52 / 74 · 0:58 · Original AXON film
Sermorelin
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Historical GEREF indications
Sermorelin has a documented medical history. FDA records describe GEREF products previously approved for particular growth-hormone testing and pediatric growth-hormone deficiency indications. [1]
FDA determination | 2013
The products were later discontinued. In 2013, FDA determined that their withdrawal from sale was not for reasons of safety or effectiveness. [1]
A specific regulatory question
That determination answers a regulatory question about those historical products. It does not demonstrate that every modern preparation is approved or clinically equivalent. [1]
New claims need matched evidence
Claims about adult recovery, body composition, or healthy aging still need evidence matched to the exact population and outcome. Historical approval alone cannot supply missing clinical trials for a different use. [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- FDA (2013): Determination that GEREF sermorelin acetate products were not withdrawn for reasons of safety or effectiveness →Historical diagnostic and pediatric indications, discontinuation, and the limited 2013 regulatory determination.
